Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beximco PharmaceuticalsSTU:R2WA +1.96%73 5-Year Yield-on-Cost % is 21.17 as of Aug. 12, 2026, which is 269% above its 10-year median of 5.74. GuruFocus rates STU:R2WA with a GF Score™ of 73/100 and a GF Value™ of €0.57 (Fairly Valued). The stock has 5 warning signs investors should review. Among 512 Drug Manufacturers companies, Beximco Pharmaceuticals ranks better than 89.84% on this metric.
The historical rank and industry rank for Beximco Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:
STU:R2WA'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.36 Med: 5.74 Max: 21.17
Current: 21.17
During the past 13 years, Beximco Pharmaceuticals's highest Yield on Cost was 21.17. The lowest was 1.36. And the median was 5.74.
STU:R2WA's 5-Year Yield-on-Cost % is ranked better than 89.84% of 512
companies
in the Drug Manufacturers industry
Industry Median: 2.28
vs STU:R2WA: 21.17
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Beximco Pharmaceuticals 5-Year Yield-on-Cost % Related Terms
STU:R2WA vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beximco Pharmaceuticals 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Beximco Pharmaceuticals's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Beximco Pharmaceuticals (STU:R2WA) has a 5-Year Yield-on-Cost % of 21.17 as of Aug. 12, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Beximco Pharmaceuticals and its competitors. This is 269% above median its historical median of 5.74. Over the past decade, Beximco Pharmaceuticals' 5-Year Yield-on-Cost % has ranged from 1.36 to 21.17. According to the industry distribution chart, Beximco Pharmaceuticals ranks #52 out of 512 companies in the Drug Manufacturers industry, placing it in the top 10.2%.
Is Beximco Pharmaceuticals' 5-Year Yield-on-Cost % too high?
Beximco Pharmaceuticals' current 5-Year Yield-on-Cost % of 21.17 is 269% above median its 10-year median of 5.74. Over the past 10 years, this metric has ranged from a low of 1.36 to a high of 21.17. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.28. Beximco Pharmaceuticals' value of 21.17 is 828.5% above this industry median. Based on the distribution chart, Beximco Pharmaceuticals ranks #52 out of 512 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Beximco Pharmaceuticals has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Beximco Pharmaceuticals ranks #52 out of 512 companies for 5-Year Yield-on-Cost %. This places Beximco Pharmaceuticals in the top 10% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.28. Beximco Pharmaceuticals' value of 21.17 is 828.5% above this benchmark. Historically, Beximco Pharmaceuticals' own 5-Year Yield-on-Cost % has ranged from 1.36 to 21.17 over the past decade. While the company's 10-year median is 5.74 vs. the industry median of 2.28, Beximco Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.28, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beximco Pharmaceuticals's current 5-Year Yield-on-Cost % of 21.17 is 828.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Beximco Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beximco Pharmaceuticals's current 5-Year Yield-on-Cost % is 21.17, which is 269% above median its own 10-year median of 5.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Beximco Pharmaceuticals (STU:R2WA) is currently considered Fairly Valued. The stock's GF Value™ is €0.57, compared to a current price of €0.52 — trading 8.8% below its estimated fair value. The current 5-Year Yield-on-Cost % is 21.17, which is 269% above median its 10-year median of 5.74 and 828.5% above the Drug Manufacturers industry median of 2.28. Beximco Pharmaceuticals' overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Beximco Pharmaceuticals (STU:R2WA), the current 5-Year Yield-on-Cost % is 21.17 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beximco Pharmaceuticals (STU:R2WA) Overvalued in 2026?
Based on GuruFocus' analysis, Beximco Pharmaceuticals stock appears to be undervalued.
The current stock price of €0.52 is trading 8.8% below its estimated GF Value™ of €0.57.
GuruFocus considers Beximco Pharmaceuticals to be Fairly Valued.
Key valuation signals for STU:R2WA:
5-Year Yield-on-Cost %: 21.17 (269% above median its 10-year median of 5.74)
GF Value™: €0.57 vs. price of €0.52 (8.8% below fair value)
Industry Position: 828.5% above the Drug Manufacturers median (#52 of 512)
No single metric tells the full story. See the STU:R2WA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
73GF Score
Get the complete analysis for STU:R2WA
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:R2WA has been successfully added to your 
